Lars N G Nilsson

List of Publications by Year
in descending order

65	3,218	147801	155660
papers	citations	31 h-index	55 g-index

68	68	68	4081
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Translation of the Alzheimer Amyloid Precursor Protein mRNA Is Up-regulated by Interleukin-1 through 5â€²-Untranslated Region Sequences. Journal of Biological Chemistry, 1999, 274, 6421-6431.	3.4	256
2	The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic mice. Neurobiology of Aging, 2006, 27, 67-77.	3.1	221
3	Imaging Distinct Conformational States of Amyloid-β Fibrils in Alzheimerâ€™s Disease Using Novel Luminescent Probes. ACS Chemical Biology, 2007, 2, 553-560.	3.4	177
4	Glial activation and inflammation along the Alzheimerâ€™s disease continuum. Journal of Neuroinflammation, 2019, 16, 46.	7.2	175
5	Sensitive ELISA detection of amyloidâ€β protofibrils in biological samples. Journal of Neurochemistry, 2007, 103, 334-345.	3.9	174
6	Loss of Astrocyte Polarization in the Tg-ArcSwe Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 711-722.	2.6	165
7	α-1-Antichymotrypsin Promotes β-Sheet Amyloid Plaque Deposition in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2001, 21, 1444-1451.	3.6	133
8	Cerebrospinal fluid soluble TREM2 in aging and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 17.	6.2	105
9	An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease. Neurobiology of Disease, 2009, 36, 425-434.	4.4	89
10	Amyloidâ€β oligomers are inefficiently measured by enzymeâ€linked immunosorbent assay. Annals of Neurology, 2005, 58, 147-150.	5.3	88
11	Animal models of amyloidâ€βâ€related pathologies in Alzheimerâ€™s disease. FEBS Journal, 2010, 277, 1389-1409.	4.7	87
12	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. Neurobiology of Aging, 2001, 22, 923-930.	3.1	79
13	Amyloidâ€β protofibril levels correlate with spatial learning in Arctic Alzheimerâ€™s disease transgenic mice. FEBS Journal, 2009, 276, 995-1006.	4.7	79
14	A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiology of Aging, 2009, 30, 1393-1405.	3.1	79
15	Heparan Sulfate Accumulation with Aβ Deposits in Alzheimer's Disease and Tg2576 Mice is Contributed by Glial Cells. Brain Pathology, 2008, 18, 548-561.	4.1	71
16	Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Neurobiology of Aging, 2004, 25, 1153-1167.	3.1	70
17	Specific Uptake of an Amyloid-β Protofibril-Binding Antibody-Tracer in AβPP Transgenic Mouse Brain. Journal of Alzheimer's Disease, 2013, 37, 29-40.	2.6	65
18	The Alzheimerâ€™s disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. Journal of Neuroinflammation, 2017, 14, 59.	7.2	59

#	Article	IF	Citations
19	Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-Î² in murine brain. Acta Neuropathologica, 2012, 124, 465-478.	7.7	57
20	Regional distribution of somatostatin receptor binding and modulation of adenylyl cyclase activity in Alzheimer's disease brain. Journal of the Neurological Sciences, 1991, 105, 225-233.	0.6	56
21	The Arctic Alzheimer mutation favors intracellular amyloid-Î² production by making amyloid precursor protein less available to Î±-secretase. Journal of Neurochemistry, 2007, 101, 854-862.	3.9	55
22	Docosahexaenoic acid stimulates nonâ€amyloidogenic APP processing resulting in reduced AÎ² levels in cellular models of Alzheimer's disease. European Journal of Neuroscience, 2007, 26, 882-889.	2.6	51
23	Elevated MARK2-Dependent Phosphorylation of Tau in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 699-713.	2.6	48
24	Genetic Deletion and Pharmacological Inhibition of Nogo-66 Receptor Impairs Cognitive Outcome after Traumatic Brain Injury in Mice. Journal of Neurotrauma, 2010, 27, 1297-1309.	3.4	42
25	Impaired behavior of female tg-ArcSwe APP mice in the IntelliCage: A longitudinal study. Behavioural Brain Research, 2010, 215, 83-94.	2.2	41
26	Overexpression of Heparanase Lowers the Amyloid Burden in Amyloid-Î² Precursor Protein Transgenic Mice. Journal of Biological Chemistry, 2015, 290, 5053-5064.	3.4	41
27	Observations in APP Bitransgenic Mice Suggest that Diffuse and Compact Plaques Form via Independent Processes in Alzheimer's Disease. American Journal of Pathology, 2011, 178, 2286-2298.	3.8	38
28	The Arctic AÎ²PP mutation leads to Alzheimerâ€™s disease pathology with highly variable topographic deposition of differentially truncated AÎ². Acta Neuropathologica Communications, 2013, 1, 60.	5.2	38
29	Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimerâ€™s transgenic mouse lines differing in AÎ² deposition. Behavioural Brain Research, 2004, 153, 107-121.	2.2	37
30	Appearance of Cxcl10â€expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders. European Journal of Neuroscience, 2010, 31, 852-863.	2.6	36
31	CSF sTREM2 in deliriumâ€”relation to Alzheimerâ€™s disease CSF biomarkers AÎ²42, t-tau and p-tau. Journal of Neuroinflammation, 2018, 15, 304.	7.2	36
32	Sensitive detection of AÎ² protofibrils by proximity ligation - relevance for Alzheimer's disease. BMC Neuroscience, 2010, 11, 124.	1.9	33
33	The Arctic amyloid-Î² precursor protein (AÎ²PP) mutation results in distinct plaques and accumulation of N- and C-truncated AÎ². Neurobiology of Aging, 2012, 33, 1010.e1-1010.e13.	3.1	31
34	The CCAAT/enhancer binding protein (C/EBP) Î´ is differently regulated by fibrillar and oligomeric forms of the Alzheimer amyloid-Î² peptide. Journal of Neuroinflammation, 2011, 8, 34.	7.2	28
35	Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease. Neurochemistry International, 2001, 39, 361-370.	3.8	27
36	Transient OGG1, APE1, PARP1 and PolÎ² expression in an Alzheimer's disease mouse model. Mechanisms of Ageing and Development, 2013, 134, 467-477.	4.6	25

#	Article	IF	Citations
37	Environmental influence on somatostatin levels and gene expression in the rat brain. Brain Research, 1993, 628, 93-98.	2.2	24
38	Cerebrospinal fluid sTREM2 in Alzheimerâ€™s disease: comparisons between clinical presentation and AT classification. Scientific Reports, 2020, 10, 15886.	3.3	23
39	The Uppsala APP deletion causes early onset autosomal dominant Alzheimerâ€™s disease by altering APP processing and increasing amyloid Î² fibril formation. Science Translational Medicine, 2021, 13, .	12.4	23
40	Important Role of Hepatitis C Virus Infection as a Cause of Chronic Liver Disease in Somalia. Scandinavian Journal of Infectious Diseases, 1993, 25, 559-564.	1.5	19
41	Brainwide distribution and variance of amyloid-beta deposits in tg-ArcSwe mice. Neurobiology of Aging, 2014, 35, 556-564.	3.1	19
42	Elevated mRNA-Levels of Gonadotropin-Releasing Hormone and Its Receptor in Plaque-Bearing Alzheimer's Disease Transgenic Mice. PLoS ONE, 2014, 9, e103607.	2.5	19
43	Genetic and pharmacological evidence of intraneuronal AÎ² accumulation in APP transgenic mice. FEBS Letters, 2009, 583, 3021-3026.	2.8	18
44	A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12128.	2.4	16
45	Effects of nucleus basalis lesion on muscarinic receptor subtypes. Experimental Brain Research, 1993, 97, 225-32.	1.5	15
46	Increased mRNA Levels ofTCF7L2andMYCof the Wnt Pathway in Tg-ArcSwe Mice and Alzheimer's Disease Brain. International Journal of Alzheimer's Disease, 2011, 2011, 1-7.	2.0	15
47	CSF sTREM2 and Tau Work Together in Predicting Increased Temporal Lobe Atrophy in Older Adults. Cerebral Cortex, 2020, 30, 2295-2306.	2.9	15
48	Impaired astrocytic Ca2+ signaling in awake-behaving Alzheimerâ€™s disease transgenic mice. ELife, 0, 11, .	6.0	15
49	Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous AÎ² deposition, in an AÎ²PP/PS double transgenic mouse model of Alzheimer's disease. Journal of Alzheimer's Disease, 2004, 6, 509-514.	2.6	13
50	Lack of exon 10 in the murine tau gene results in mild sensorimotor defects with aging. BMC Neuroscience, 2013, 14, 148.	1.9	11
51	USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE. Technology and Innovation, 2012, 14, 199-208.	0.2	10
52	¹¹C and ¹⁸F Radiolabeling of Tetra- and Pentathiophenes as PET-Ligands for Amyloid Protein Aggregates. ACS Medicinal Chemistry Letters, 2016, 7, 368-373.	2.8	10
53	Systemic LPS-induced AÎ²-solubilization and clearance in AÎ²PP-transgenic mice is diminished by heparanase overexpression. Scientific Reports, 2019, 9, 4600.	3.3	10
54	Characterization and quantification of 125I-bolton hunter substance P binding sites in human brain. Neurochemistry International, 1991, 18, 399-404.	3.8	9

#	Article	IF	Citations
55	Identification of amyloid beta mid-domain fragments in human cerebrospinal fluid. Biochimie, 2015, 113, 86-92.	2.6	8
56	Decrease of somatostatin receptor binding in the rat cerebral cortex after ibotenic acid lesion of the nucleus basalis magnocellularis: a quantitative autoradiographic study. Brain Research, 1993, 628, 31-38.	2.2	7
57	Isobaric Quantification of Cerebrospinal Fluid Amyloid-Î² Peptides in Alzheimerâ€™s Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Journal of Proteome Research, 2015, 14, 4834-4843.	3.7	7
58	Coexistence of somatostatin receptor subtypes in the human neuroblastoma cell line LA-N-2. FEBS Letters, 1997, 401, 83-88.	2.8	6
59	Somatostatinergic phenotype markers in the human neuroblastoma cell-line LA-N-2. FEBS Letters, 1995, 372, 88-92.	2.8	4
60	Influence of place learning on somatostatin levels in the rat brain following environmental deprivation. Regulatory Peptides, 1995, 58, 11-18.	1.9	3
61	Analyzing microglial-associated AÎ² in Alzheimerâ€™s disease transgenic mice with a novel mid-domain AÎ²-antibody. Scientific Reports, 2020, 10, 10590.	3.3	3
62	Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. Nutrition Reviews, 2010, 68, S128-S134.	5.8	2
63	Diminution of preprosomatostatin-mRNA in cerebral cortex of the aged rat. Neurochemistry International, 1995, 27, 481-487.	3.8	1
64	An improved CPRG colorimetric ligand-receptor signal transduction assay based on beta-galactosidase activity in mammalian BWZ-reporter cells. Journal of Pharmacological and Toxicological Methods, 2018, 90, 67-75.	0.7	1
65	Local impact of perivascular plaques on cerebral blood flow dynamics in a transgenic mouse model of Alzheimer's disease. , 2008, , .		0